NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) resulting from allegations that Eagle Pharmaceuticals may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Eagle Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=20722 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On November 9, 2023, Eagle issued a press release stating that "it will be delaying the release of its third quarter 2023 results and investor conference call, ...